Orexo has been granted a patent for a method to treat opioid dependence in patients misusing alcohol. The approach involves administering buprenorphine and naloxone alongside a self-directed digital cognitive behavioral therapy program to reduce alcohol consumption and enhance treatment adherence. GlobalData’s report on Orexo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Orexo, Cancer treatment biomarkers was a key innovation area identified from patents. Orexo's grant share as of June 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating opioid dependence with alcohol management
The granted patent US11986472B1 outlines a method for treating opioid dependence in patients who are also consuming alcohol. The treatment involves administering a sublingual dose of buprenorphine and naloxone, which is designed to effectively manage withdrawal symptoms and cravings associated with opioid use. In conjunction with this pharmacological approach, patients engage with a self-directed digital, interactive cognitive behavioral therapy (CBT) program aimed at reducing alcohol consumption. This dual approach is intended to enhance patient adherence to the treatment regimen by addressing both opioid dependence and concurrent alcohol use.
The patent further details the structure of the cognitive behavioral therapy program, which may include a web-based software platform featuring multiple modules that utilize various psychotherapeutic techniques. Specific modules mentioned include those focused on patient drinking patterns, alcohol craving control, coping with risk situations, and relapse prevention. The sublingual dose of buprenorphine is specified to range from 0.7 mg to 11.4 mg, while naloxone is administered in doses from 0.18 mg to 2.9 mg, taken once daily. The timing of the CBT engagement can occur before, during, or after the administration of the medication, with the possibility of overlapping sessions to maximize therapeutic effectiveness. This comprehensive approach aims to support patients diagnosed with alcohol use disorder while managing their opioid dependence.
To know more about GlobalData’s detailed insights on Orexo, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
